The Artificial Intelligence Center of Novosibirsk State University (NSU) has developed and patented a program called Safe Medicines for selecting therapy taking into account the individual characteristics of the patient.
“The development makes it possible to assess the compatibility of drugs with each other, possible side effects, and the impact of medications on specific clinical and laboratory parameters,” the university’s press service reported.
The relevance of the development is driven by the increasing number of patients receiving combination therapy. “Today, there are practically no patients with a single problem. A doctor faces a situation where they need to prescribe five or six drugs while simultaneously considering their interactions, side effects, and the patient’s individual parameters,” said the project leader, Vladimir Ivanisenko, a leading researcher at the NSU Artificial Intelligence Center.
Furthermore, each drug has its own side effects and can affect the body differently depending on age, concomitant diseases, and test results. As a result, doctors have to consider dozens of factors simultaneously.
Automating such analysis helps avoid missing important details and reduces the likelihood of medical errors. Unlike other drug selection systems, “Safe Medicines” analyzes not only standard treatment regimens and drug interactions but also the specific clinical picture of the patient — laboratory parameters, symptoms, and concomitant conditions.
The development is part of the Doctor Pirogov project — a digital assistant for supporting clinical decision-making. The system integrates knowledge from 20 medical specialties and contains information on more than 250 diseases.
